(Total Views: 596)
Posted On: 08/31/2020 10:10:16 AM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
I’m very positive on LL but the trial should of never included mild patients . Heads should roll for that decision . Multiples people probably . As I have said in the past the price point for mild patients if ever rolled out would kill pricing for every other indication . This is and should a drug on par with rem.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)